Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...
(RTTNews) - Roche (RHHBY) said FDA has approved Actemra/RoActemra subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results